• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Anti-PD-1 Treatment Selection

Video

During this segment, Richard W. Joseph, MD, describes the effectiveness of the anti-PD-1 agents pembrolizumab and nivolumab, and discusses similarities and differences between the 2 drugs.

Dr Joseph explains that although no head-to-head trials have directly compared the 2 agents, cross-trial comparisons have demonstrated that they are similar in terms of safety and efficacy. For this reason, he questions why the FDA approved pembrolizumab after just a phase 1 study but required a phase 3 study prior to approving nivolumab.

One difference between the 2 drugs, he notes, is that while nivolumab is administered every 2 weeks, pembrolizumab is given every 3 weeks.

Dr Joseph suggests that unless proved otherwise, the agents should be considered equivalent by managed care organizations and payer coverage should be the same for both drugs.


Related Videos
Jaime Almandoz, MD, MBA
Martin Edelman, MD
Benjamin Chen, MD, PhD
4 experts are featured in this series.
1 expert is featured in this series.
4 experts are featured in this series.
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Pierluigi Porcu, MD
4 experts are featured in this series.
5 experts are featured in this series
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.